3-羟基-1-甲基异喹啉 | 16535-89-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 3-羟基-1-甲基异喹啉
• 中文别名: 1-甲基异喹啉-3-醇
• 英文名称: 3-Hydroxy-1-methyl-isochinolin
• 英文别名: 1-methyl-2H-isoquinolin-3-one
• CAS: 16535-89-0
• 化学式: C₁₀H₉NO
• mdl: MFCD11053887
• 分子量: 159.188
• InChiKey: WZERFHYFSWMIRV-UHFFFAOYSA-N

物化性质

• 熔点：
  204 °C (decomp)(Solv: ethanol (64-17-5))
• 沸点：
  507.3±23.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methylisoquinolin-3-ol
Synonyms: 3-Hydroxy-1-methylisoquinoline; 1-methyl-2h-isoquinolin-3-one

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methylisoquinolin-3-ol
CAS number: 16535-89-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9NO
Molecular weight: 159.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-羟基-1-甲基异喹啉 在 吡啶 、 potassium phosphate 、 甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(II) 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-(furan-2-yl)-1-methylisoquinoline
  参考文献：
  名称：

  铱催化的1，3-二取代异喹啉的对映选择性和非对映选择性加氢

  摘要：

  据报道，开发了一种利用羟甲基指导基团进行1,3-二取代异喹啉不对称氢化以提供手性1,2,3,4-四氢异喹啉的一般方法。利用[Ir（cod）Cl] 2的反应以及市售的手性木二酚配体，在一系列差异取代的异喹啉上，均具有良好的收率，并具有高水平的对映选择性和非对映选择性（高达95％ee和> 20：1 dr）。指导基研究表明，尽管在各种极性和非极性官能团上均保留了高水平的对映选择性，但与其他取代基相比，C1位置的羟甲基官能团在加氢方面更有效。通过利用生成的手性β-氨基醇作为功能性手柄，通过一步合成1，2-稠合的恶唑烷，恶唑烷酮和吗啉酮四氢异喹啉可以进一步突出合成用途。另外，

  DOI：

  10.1021/acscatal.0c00211
• 作为产物：
  描述：

  2-(2-溴苯基)-2-甲基-1,3-二氧戊环 在 ammonium hydroxide 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三氟乙酸 、 lithium hexamethyldisilazane 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 32.0h， 生成 3-羟基-1-甲基异喹啉
  参考文献：
  名称：

  铱催化的1，3-二取代异喹啉的对映选择性和非对映选择性加氢

  摘要：

  据报道，开发了一种利用羟甲基指导基团进行1,3-二取代异喹啉不对称氢化以提供手性1,2,3,4-四氢异喹啉的一般方法。利用[Ir（cod）Cl] 2的反应以及市售的手性木二酚配体，在一系列差异取代的异喹啉上，均具有良好的收率，并具有高水平的对映选择性和非对映选择性（高达95％ee和> 20：1 dr）。指导基研究表明，尽管在各种极性和非极性官能团上均保留了高水平的对映选择性，但与其他取代基相比，C1位置的羟甲基官能团在加氢方面更有效。通过利用生成的手性β-氨基醇作为功能性手柄，通过一步合成1，2-稠合的恶唑烷，恶唑烷酮和吗啉酮四氢异喹啉可以进一步突出合成用途。另外，

  DOI：

  10.1021/acscatal.0c00211

文献信息

• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] COMBINATION THERAPIES FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIES COMBINATOIRES POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2016044772A1

  公开（公告）日：2016-03-24

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供用于治疗与KRAS基因突变相关的癌症的联合疗法。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。
• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE RAS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018068017A1

  公开（公告）日：2018-04-12

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1, n2and '--" are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also disclosed.

  提供了具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、立体异构体或前药，其中A、B、R"、Q、W、X、Y、Z、n1、n2和'--'的定义如本文所述。还公开了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• NOVEL CYP-EICOSANOID DERIVATIVES
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：US20170008918A1

  公开（公告）日：2017-01-12

  The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for C the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

  本发明涉及一般式（I）的化合物，这些化合物是由细胞色素P450（CYP）酶从ω-3（n-3）多不饱和脂肪酸（PUFAs）产生的环氧代谢产物的类似物。本发明还涉及含有这些化合物中的一个或多个的组合物，以及利用这些化合物或组合物用于治疗或预防与炎症、增殖、高血压、凝血、免疫功能、病理性血管生成、心力衰竭和心律失常相关的疾病和症状。
• [EN] BENZOTHIOPHENE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS À BASE DE BENZOTHIOPHÈNE ET DE BENZOTHIAZOLE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140599A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）或其药用可接受的盐、立体异构体或前药，其中B、Z、Ra、Rb、Rc、R1、L、L1和E如本文所定义。还提供了与制备和使用此类化合物相关的方法，包括含有这些化合物的药物组合物以及用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。